Drugs / Dengvaxia
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Withdrawn | EU (EMA) | Dengvaxia | — | 2025-10-21 | europa.eu ↗ |
| Approved | EU (EMA) | Dengvaxia | — | 2018-12-12 | europa.eu ↗ |
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 0 | NCT05476757 Background | Aug 2022 → Jan 2023 | dengue disease | Mahidol University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dengvaxia | “the participants will be vaccinated with Dengvaxia® until completion of 3 doses with 6-month interval between each dose.” NCT05476757 ↗ |
| Modality | Vaccine | “the participants will be vaccinated with Dengvaxia®” NCT05476757 ↗ |